Recombinant human monoclonal antibody to Cannabinoid Receptor I.
Applicazioni
ELISA, FACS, Functional Assay, In Vivo
Reattività
Human, Cynomolgus Macaque
Specie ospite
Human
Clonalità
Monoclonal
Isotipo
IgG4
Catene leggere
kappa
Coniugare
Unconjugated
Purificazione
Protein A affinity chromatography.
Concentrazione
Reconstitution dependent.
Peso molecolare
This antibody has a predicted MW of 145 kDa.
Purezza
> 95% (by SDS-PAGE and SEC-HPLC).
Forma del prodotto
Lyophilized
Ricostituzione
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulazione
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Conservazione
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
SDS-PAGE analysis of Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607) under reducing (R) conditions confirms that the purity of this antibody is greater than 95%.
SEC-HPLC analysis of Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607) confirms that the purity of this antibody is 99.42%.
Immobilized recombinant human CB1 VLP protein at 5 µg/ml (30 uL/well) is bound by Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607). EC50 was approximately 0.04092 µg/ml.
Human CB1 / CNR1 EGFP HEK293 Cell Line were stained with Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607) and negative control protein respectively, washed and then followed by APC and analyzed with FACS, EC50 = 0.028 µg/ml.
Prodotti alternativi a Anti-Cannabinoid Receptor I Anticorpo (A323607)